Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial
Atsushi Nakajima(Yokohama City University), Shinya Taniguchi(Konan University), Mitsunori Seki(EA Pharma (Japan))
Cited by 62
Related Papers
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease
|JAMA|2024|200
Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial
|The Lancet. Gastroenterology & hepatology|2018|174